Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC lowered its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 21.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,720 shares of the company’s stock after selling 4,820 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Recursion Pharmaceuticals were worth $120,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RXRX. Exchange Traded Concepts LLC grew its position in Recursion Pharmaceuticals by 24.9% during the third quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company’s stock valued at $166,000 after buying an additional 5,021 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at about $70,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at about $25,000. Foundations Investment Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 25.0% in the third quarter. Foundations Investment Advisors LLC now owns 193,036 shares of the company’s stock valued at $1,272,000 after purchasing an additional 38,642 shares during the period. Finally, Private Advisor Group LLC grew its position in shares of Recursion Pharmaceuticals by 28.6% in the third quarter. Private Advisor Group LLC now owns 15,419 shares of the company’s stock valued at $102,000 after purchasing an additional 3,432 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $10.53 on Friday. The company’s 50-day moving average price is $7.27 and its 200-day moving average price is $6.91. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $4.11 billion, a P/E ratio of -6.88 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74.

Analyst Ratings Changes

Several analysts have recently issued reports on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.